Krakoff et al. (2010) reported that metformin steadily lowers serum ALT; nevertheless, body weight management and lifestyle alteration remain the principal priorities of the NAFLD therapeutic intervention strategy [211]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.